Linked Life Data

14506952

Source:http://linkedlifedata.com/resource/pubmed/id/14506952

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2003-9-24
pubmed:abstractText
We report a prospective, randomized, multicenter, open-label 2-year trial of 81 postmenopausal women aged 53-79 years with at least one minimal-trauma vertebral fracture (VF) and low (T-score below - 2) lumbar bone mineral density (BMD). Group HRT received piperazine estrone sulfate (PES) 0.625 - 1.25 mg/d +/- medroxyprogesterone acetate (MPA) 2.5 - 5 mg/d; group HRT/D received HRT plus calcitriol 0.25 microg bd. All with a baseline dietary calcium (Ca) of < 1 g/ d received Ca carbonate 0.6 g nocte. Final data were on 66 - 70 patients. On HRT/D, significant (P < 0.001) BMD increases from baseline by DXA were at total body - head, trochanter, Ward's, total hip, intertrochanter and femoral shaft (% group mean delta 4.2, 6.1, 9.3, 3.7, 3.3 and 3.3%, respectively). On HRT, at these 6 sites, significant deltaS were restricted to the trochanter and Wards. Significant advantages of HRT/D over HRT were in BMD of total body (- head), total hip and trochanter (all P = 0.01). The differences in mean delta at these sites were 1.3, 2.6 and 3.9%. At the following, both groups improved significantly -lumbar spine (AP and lateral), forearm shaft and ultradistal tibia/fibula. The weightbearing, site - specific benefits of the combination associated with significant suppression of parathyroid hormone-suggest a beneficial effect on cortical bone. Suppression of bone turnover was significantly greater on HRT/D (serum osteocalcin P = 0.024 and urinary hydroxyproline/creatinine ratio P = 0.035). There was no significant difference in the number of patients who developed fresh VFs during the trial (HRT 8/36, 22%; HRT/D 4/34, 12% - intention to treat); likewise in the number who developed incident nonvertebral fractures. This is the first study comparing the 2 treatments in a fracture population. The results indicate a significant benefit of calcitriol combined with HRT on total body BMD and on BMD at the hip, the major site of osteoporotic fracture.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0171-967X
pubmed:author
pubmed:issnType
Print
pubmed:volume
73
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
33-43
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:14506952-Absorptiometry, Photon, pubmed-meshheading:14506952-Aged, pubmed-meshheading:14506952-Biological Markers, pubmed-meshheading:14506952-Bone Density, pubmed-meshheading:14506952-Calcitriol, pubmed-meshheading:14506952-Drug Therapy, Combination, pubmed-meshheading:14506952-Estrogen Replacement Therapy, pubmed-meshheading:14506952-Estrogens, Conjugated (USP), pubmed-meshheading:14506952-Estrone, pubmed-meshheading:14506952-Female, pubmed-meshheading:14506952-Hip Joint, pubmed-meshheading:14506952-Humans, pubmed-meshheading:14506952-Hydroxyproline, pubmed-meshheading:14506952-Medroxyprogesterone Acetate, pubmed-meshheading:14506952-Middle Aged, pubmed-meshheading:14506952-Osteocalcin, pubmed-meshheading:14506952-Osteoporosis, Postmenopausal, pubmed-meshheading:14506952-Quality of Life, pubmed-meshheading:14506952-Severity of Illness Index, pubmed-meshheading:14506952-Single-Blind Method, pubmed-meshheading:14506952-Spinal Fractures, pubmed-meshheading:14506952-Treatment Outcome
pubmed:year
2003
pubmed:articleTitle
A randomized trial comparing hormone replacement therapy (HRT) and HRT plus calcitriol in the treatment of postmenopausal osteoporosis with vertebral fractures: benefit of the combination on total body and hip density.
pubmed:affiliation
Department of Endocrinology, Sir Charles Gairdner Hospital, Verdun Street, Nedlands, Western Australia 6009, Australia, dhgutteridge@bigpond.com
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study